Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase payment to administer them in most other care settings to $450 from $310 to better align payment with provider costs, the Centers for Medicare & Medicaid Services announced yesterday. CMS is updating its COVID-19 toolkits and coding resources to reflect the new payment rates.

Related News Articles

Headline
The AHA today joined the Department of Health and Human Services, Centers for Disease Control and Prevention, and other national health care and public health…
Headline
The Health Resources and Services Administration has reimbursed more than 5 million claims to administer COVID-19 vaccine to uninsured individuals, the agency…
Headline
The Department of Health and Human Services today announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered…
Headline
The Centers for Disease Control and Prevention June 11 updated requirements for health care providers participating in the COVID-19 Vaccination Program to…
Headline
The Food and Drug Administration yesterday authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson &…
Headline
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of…